Patients with EGFR mutations may be more sensitive to changes in hormonal and inflammatory responses in vivo, indicating the need for individualized formulation of management measures for lung cancer in pregnancy with specific driver mutations. This evidence concerns the gene EGFR and lung carcinoma.